董秘： 您好，公司始终致力于通过提升内在价值推动高质量发展，并持续推进BD合作相关事宜，进一 步推进公司多元化转型升级，但相关合作的达成会受到多重不确定性因素影响，后续如有相关达到信息 披露标准的情况，公司会按照法律法规要求履行披露义务，谢谢！ 投资者： 公司的GenSci074是否有BD潜力，是否有潜在方在接触洽谈。 董秘： 您好，如有相关达到信息披露标准的情况，公司会按照法律法规要求履行披露义务，经营情况 请持续关注公司公告等，谢谢！ 投资者： 董秘，贵公司还有无在谈的BD出海项目？不需要公布项目名称，仅告知有无便可 截至2025年12月23日收盘，长春高新(000661)报收于93.69元，下跌1.58%，换手率1.35%，成交量5.4万 手，成交额5.08亿元。 董秘最新回复 投资者： 董秘，公司还有什么药品有bd潜力 董秘： 您好，对于公司在研创新管线情况可参见公司定期报告及相关招股说明书中的介绍内容，公司 会结合战略布局、实际研发管线先进性、市场认可度等积极推进相关BD事宜，但最终是否能达成会受 到多种情况因素影响，如有达到披露标准的情况公司会及时履行披露义务，具体还请持续关注公司相关 公告。谢谢 ...

Core Viewpoint - Changchun High-tech aims to enhance its international presence and innovation capabilities by issuing H-shares for listing on the Hong Kong Stock Exchange, with funds primarily allocated for R&D, clinical trials, and international market expansion [1][3]. Fundraising Purpose - The funds raised will be used for two main directions: advancing the innovation pipeline, including clinical trials and regulatory affairs, and establishing a commercial team overseas for global collaboration and market expansion [1][3]. Financial Performance - Since 2022, Changchun High-tech's stock price has experienced significant fluctuations due to rumors surrounding the centralized procurement of growth hormones, culminating in a decline in both revenue and net profit for the first time in nearly two decades in 2024 [3]. Innovation Pipeline - The company has over 40 projects in clinical stages or IND applications, including 11 Class I innovative biological agents and 4 Class I innovative chemical drugs, focusing on endocrine and metabolic diseases, women's health, immune and respiratory systems, and oncology [3][4]. Key Products - GenSci134, a long-acting growth hormone, is currently undergoing Phase I clinical trials for adult growth hormone deficiency and has received IND approval for pediatric growth hormone deficiency and idiopathic short stature [4][5]. - GenSci074, an NK3R antagonist for treating vasomotor symptoms in menopausal women, is in Phase II clinical trials, with competition from other drugs in the same category [7][8]. Oncology Pipeline - The company is developing several innovative drugs targeting prostate, breast, and ovarian cancers, including GenSci139, GenSci140, and GenSci143, which are expected to enter Phase I clinical trials by Q4 2025 [10][11]. - GenSci139 targets low-expressing HER2 tumors and faces a competitive landscape with existing ADC therapies [11][12]. - GenSci140 aims to expand patient coverage for FRα-positive cancers and is the only FRα dual-target ADC in development in China [13][14]. - GenSci143 targets both B7-H3 and PSMA antigens, potentially offering broader patient coverage but is still in early development stages [15]. Other Therapeutic Areas - GenSci098 is a TSHR antagonist for treating thyroid-associated ophthalmopathy, indicating the company's diversification into immune and respiratory diseases [16].